A major Cochrane review found no convincing evidence that ketamine or similar NMDA-blocking drugs improve chronic non-cancer ...

A sweeping review of 67 trials has cast doubt on the use of ketamine and similar NMDA receptor antagonists for chronic pain ...

The off-label use of ketamine to treat chronic pain is not supported by scientific evidence, a new Cochrane review has found.

Researchers cautioned that the existing evidence base is too poor to draw any solid conclusions on whether ketamine can help ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

NMDA receptor antagonists are a group of medicines that affect the excitability of nerves involved in pain and other brain functions. They include ketamine, memantine, dextromethorphan, amantadine, ...

Ketamine is regularly used for the treatment of chronic pain, but a new report shows there is no clear evidence of its benefit.The off-label use of ...

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company ...

Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based implant designed to ...

Li’s study, “TIAM1-mediated synaptic plasticity underlies comorbid depression-like and ketamine antidepressant-like actions in chronic pain," was recently published in The Journal of Clinical ...

Oct. 6, 2004 — Low-dose ketamine may be effective for the treatent of chronic regional pain syndrome (CRPS), according to a retrospective review published in the October issue of Pain Medicine.